glycine has been researched along with Dyskinesia, Drug-Induced in 13 studies
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "While Parkinson's disease (PD) phenotype in leucine-rich repeat kinase 2 gene (LRRK2)-associated and sporadic PD seems similar, there is paucity of data on the possible effect of mutations in LRRK2 on response to and complications of dopaminergic therapy." | 1.38 | Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. ( Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bourque, M | 3 |
| Grégoire, L | 3 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 3 |
| Solís, O | 1 |
| García-Sanz, P | 1 |
| Herranz, AS | 1 |
| Asensio, MJ | 1 |
| Moratalla, R | 1 |
| Paus, S | 1 |
| Gadow, F | 1 |
| Knapp, M | 1 |
| Klein, C | 1 |
| Klockgether, T | 1 |
| Wüllner, U | 1 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Yahalom, G | 1 |
| Kaplan, N | 1 |
| Vituri, A | 1 |
| Cohen, OS | 1 |
| Inzelberg, R | 1 |
| Kozlova, E | 1 |
| Korczyn, AD | 1 |
| Rosset, S | 1 |
| Friedman, E | 1 |
| Hassin-Baer, S | 1 |
| Zhang, Z | 1 |
| Hou, G | 1 |
| Zhang, X | 2 |
| Yao, H | 1 |
| Sha, W | 1 |
| Shoham, S | 1 |
| Mazeh, H | 1 |
| Javitt, DC | 1 |
| Heresco-Levy, U | 2 |
| Bakker, PR | 1 |
| van Harten, PN | 1 |
| van Os, J | 1 |
| Hammond, EJ | 1 |
| Wilder, BJ | 1 |
| Bruni, J | 1 |
| Segman, R | 1 |
| Neeman, T | 1 |
| Finkel, B | 1 |
| Karagichev, L | 1 |
| Schlafman, M | 1 |
| Dorevitch, A | 1 |
| Yakir, A | 1 |
| Lerner, A | 1 |
| Shelevoy, A | 1 |
| Lerer, B | 2 |
| Dawson, L | 1 |
| Chadha, A | 1 |
| Megalou, M | 1 |
| Duty, S | 1 |
| Segman, RH | 1 |
| Fangerau, H | 1 |
| Daly, AK | 1 |
| Basile, VS | 1 |
| Cavallaro, R | 1 |
| Aschauer, HN | 1 |
| McCreadie, RG | 1 |
| Ohlraun, S | 1 |
| Ferrier, N | 1 |
| Masellis, M | 1 |
| Verga, M | 1 |
| Scharfetter, J | 1 |
| Rietschel, M | 1 |
| Lovlie, R | 1 |
| Levy, UH | 1 |
| Meltzer, HY | 1 |
| Kennedy, JL | 1 |
| Steen, VM | 1 |
| Macciardi, F | 1 |
| Vamvakidès, A | 1 |
3 reviews available for glycine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Central actions of valproic acid in man and in experimental models of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Action Potentials; Alcohol Oxidoreductases; Aldehyde Oxidoreductases; | 1981 |
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.
Topics: Adult; Aged; Analysis of Variance; Chi-Square Distribution; Confidence Intervals; Dyskinesia, Drug-I | 2002 |
[Effect of glycine-steatamide or glutamic acid palmitamide on oral dyskinesia, obtained by a single administration of haloperidol combined with GABA-linoleamide in rats].
Topics: Animals; Drug Combinations; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Glutamates; G | 1988 |
10 other studies available for glycine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; | 2016 |
Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Community Networks; Dyskinesia, Drug-Induced; Female; | 2009 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Freq | 2012 |
[Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Topics: Aged; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genetic Varia | 2003 |
Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Cycloserine; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycine; Haloperidol; Mastic | 2004 |
Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.
Topics: Alleles; Antipsychotic Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Glycine; H | 2006 |
Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genotype; Glycine; Humans; Israel; Je | 1999 |
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Cyclopropanes; Dyskinesia, Drug-Induced; Glycine; In | 2000 |